Biotech drugs vs. generics, more debate in FDA conference

02/10/2005 | Washington Post, The

The FDA conference next week will assess whether generic drugmakers have the ability to manufacture "follow-on" versions of expensive biologics. Generic drugmakers say the science of biopharmaceuticals has advanced to the point where it is possible to get lower-costing biologics on the market. But brand drugmaker trade associations, including the Biotechnology Industry Organization, argue it is much harder to reverse-engineer a biologic than it is a small molecule drug because of the complications inherent in trying to duplicate complicated and variable proteins that biologics contain.

View Full Article in:

Washington Post, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR